Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, ...

Scientists have made many advances using traditional CRISPR technology, especially in medicine, but they are now seeking ways ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping the future of medicine and genetics.

Researchers are investigating the potential of CRISPR in relation to Down syndrome.

A woman born with almost no functional vision because of a genetic mutation has regained measurable sight after a single ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your ...

SAN DIEGO & BRISBANE, Calif.--(BUSINESS WIRE)--VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a non-exclusive license agreement with Mammoth Biosciences, ...

A research team from Helmholtz Munich and the Technical University of Munich has developed an advanced delivery system that transports gene-editing tools based on the CRISPR/Cas9 gene-editing system ...

In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $48.57, marking a -5.45% move from the previous day. The stock trailed the S&P 500, which registered a daily loss of 0.51%.